peptides]) that is ''highly similar'' to the reference product. 2, [4] [5] [6] [7] [8] [9] [10] [11] The meaning of ''highly similar'' is not fully explained by the FDA. These compounds are more difficult to produce than generics. Small changes in the manufacturing process (eg, changes in type of expression system, changes in environmental conditions, changes in the engineered cell line) may result in slightly different compounds, which may act differently within the biologic system or cause peptide denaturation, aggregation, oxidation, or degradation during the manufacturing process. [6] [7] [8] [9] The review and decision by the FDA will be based on its evaluation of all available data and will use a totality-of-the-evidence approach. This process would involve a stepwise approach to the development of the evidence to support an application that clearly demonstrates the biological products' similarity to the reference product. 1, 10, 11 The review will include an evaluation of the structural and functional characteristics of the product, human pharmacokinetics and pharmacodynamic data, clinical knowledge of the reference product (eg, postmarket experience), clinical immunogenicity, animal studies, and clinical studies. 2 To be approved, the biological product needs to be biosimilar to the reference product; it needs to be ''highly similar'' to the reference product, notwithstanding minor differences in clinically inactive components; and it should utilize the same mechanism(s) of action for the proposed condition and have the same route of administration, dosage form, and strength as the reference product. The condition(s) of use proposed in its labeling will have been previously approved for the reference product. There should be no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product. 2 Unlike therapeutic equivalent generic drugs, biosimilar products (so-called biogeneric products) may not be interchangeable. [9] [10] [11] More work and scientific *Director, Drug Information Center, College of Pharmacy, Washington State University Spokane proof are needed before routine therapeutic interchanges can occur in practice. Approval of a biosimilar does not automatically mean that it is safe and effective for all the same medical indications as the reference product. The working definition of interchangeable or interchangeability applies to a biological product that is biosimilar to the reference product; is expected to produce the same clinical result as the reference product in any given patients; and, if the product is administered more than once, the safety and reduced efficacy risks of alternating or switching are not greater than with repeated use of the reference product without alternating or switching. 2, [9] [10] [11] The classification as ''interchangeable'' would allow the health care system to substitute the biosimilar product for the reference product without the authorization of the prescriber. 2 One of the first biosimilar products to be approved in the United States is tbo-filgrastim. The biological license application for tbo-filgrastim (Neutroval) submitted by Sicor Biotech was approved by the FDA in August 2012. This is a biosimilar form of recombinant filgrastim. It is approved for use in the treatment of nonmyeloid malignancies treated with myelosuppressive chemotherapy. 12 The product is expected to be launched by Teva in November 2013. 13 The ''tbo'' portion of the drug name has no apparently meaning, but it is intended to distinguish it from filgrastim.
Initially, we may see biosimilar products being used in naïve patients, but not in patients who are already using the reference product as part of a treatment regimen or maintenance therapy. In naïve patients, there will be less concern with the risk of immunogenicity. These patients have not been exposed to the biological product, so there will be no risk of existing antibodies or the development of antibodies against the complex molecule because of small differences in structure or other components of the product. Interchanges between products may need to wait until we have proof of lack of immunogenicity. In the case of tbo-filgrastim, some health care providers will choose to start only filgrastimnaïve patients on this biosimilar product until there is published evidence of safety and efficacy associated with switching patients from filgrastim to tbofilgrastim. Studies such as the one with interferon beta-1a in which patients were prescribed either Avonex and CinnoVex (biosimilar) cannot answer this type of questions. The Avonex-CinnoVex study found no difference in the quality of life assessment of the multiple sclerosis patients treated with either of these products, but it was a parallel study with no crossover. 14 Until we have the crossover studies, the use of biosimilars may be limited to treatment-naïve patients. Even this limited use may save money for the health care system, because of the competitive price environment that will be created by the availability of biosimilar products.
